1Gibb A, Deeks ED. Vortioxetine: first global approval [J]. Drugs, 2014, 74 (1) : 135-145.
2US FDA. FDA approves new drug to treat major depressive disorder [EB/OL]. [2013-09-301. http://www.fda.gov/news events/newsroom/pressannouncements/ucm370416.htm.
3du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose- dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism [J]. Eur Neuropsychopharmacol, 2014, 24 (1) : 160-171.
4Andersen K, Bang-Andersen B, Moltzen EK, et al. Phenyl- piperazine derivatives as serotonin reuptake inhibitors: US, 7144884 [P]. 2006-12-05.
5Bang-Andersen B, Faldt A, de Diego HL, et al. Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition and uses thereof: US, 8299095 [P]. 2012-10-30.
6Novi M, Garbarino G, Petrillo G, et al. Electrochemical reduction of some o-bis (phenylsulphonyl) benzenederivatives. Effect of the substrate structure and of the addition of bases on the product distribution [J]. J Chem Soc Perkin Trans 2, 1987, (5):623-631.
7Nicolajsen HV, De Diego HL, Rock MH. Purification of 1- [2- (2,4-dimethylphenylsulfanyl) phenyl] piperazine: US, 8598348 [P]. 2013-12-03.
